Eric Lefkofsky has announced that Tempus will collaborate with Feist-Weiller Cancer Center to take the fight against cancer to the next level. The tech comppany and the cancer center will work together in performing research intended to help cancer patients to live better and longer lives. Co-founded by Eric Lefkofsky, Tempus is a tech company that collects and analyzes clinical data as well as molecular data.
Tempus focuses on the analysis of data such as DNA, RNA, as well as proteomic data by conducting genomic testing. This is in an effort to enable physicians to plan better treatments for each individual patient. It also organizes radiology scans, lab results, pathology images as well as clinical notes to enable physicians to have a better understanding on the clinical context of each case.
Tempus has built a reputation as a company which is supporting physicians’ efforts to come up with effective treatment for cancer patients. The data also make examination of patients in regards to molecular profiles easier as well as determine strong insights generated by machine-learning algorithms as well as advanced analytics. Eric Lefkofsky has expressed confidence that Tempus will help cancer patients to not only live longer, but also lead healthier lives through artificial intelligence.
Tempus has committed to work with Dr. Maria-Magdalena Georgescu to establish a better understanding of glioblastoma, metastatic brain disease as well as breast cancer of NLCLC. In the collaboration, Tempus has been put in-charge of genomic sequencing and clinical data structuring for patients of Dr. Georgescu. Tempus has always strived to use machine learning and other capabilities to find patterns that may prove relevant in regards to how cancer patients respond to therapy.
Feist-Weiller Cancer Center was started in 1997 and it grew to become a large cancer center which performs research as well as provides training to future cancer care providers. Feist-Weiller Cancer Center has always been focused on marginalized areas and underserved communities to make sure cancer patients have access to the National Cancer Institute clinical research trials.
On the other hand, Tempus was co-founded by Eric Lefkofsky with one mission in sight: to make relevant data available and accessible to physicians for effective administration of treatments to patients. Since its founding, the company has brought together a team of experts including bioinformaticians, engineers, scientists, computational biologists, physicians and more to empower physicians to make not only real-time decisions, but also data-driven decisions.